FDA warns against unauthorized 'smart' e-cigarettes for youth

Oct.31.2024
FDA warns against unauthorized 'smart' e-cigarettes for youth
FDA has issued warnings to nine online retailers and one manufacturer, accusing them of selling unapproved e-cigarettes. These products are designed to appeal to youth with "smart" features such as gaming, smartphone connectivity, and text messaging capabilities, while concealing the true nature of their tobacco content.

FDA announced that it has issued warning letters to nine online retailers and one manufacturer on October 30, accusing them of selling and/or distributing unapproved disposable e-cigarettes. 

 

These products have designs and features similar to smart technology, including capabilities similar to those of mobile phones and gaming devices.

 

The products mentioned in the warning letters are marketed with various features designed to appeal to young people, such as the ability to play games, connect to smartphones, receive text messages or call notifications, play music, or personalize the device with custom wallpapers.

 

"These products may resemble smart devices, but there's nothing smart about them," said Brian King, Ph.D., M.P.H., director of FDA's Center for Tobacco Products. "They're illegal to sell and a flagrant attempt to target kids." (According to FDA's ctp-newsroom.)

 

Additionally, the design of these unauthorized products may attract young users by helping conceal their nature as tobacco products from parents, teachers, or other adults. The warning letters include comparison images showing these unauthorized products alongside common consumer electronic devices.

 

FDA warns against unauthorized 'smart' e-cigarettes for youth
Example image | Image source: FDA

 

FDA warns against unauthorized 'smart' e-cigarettes for youth
Example image | Image source: FDA

 

The companies receiving these warning letters are involved in selling and/or distributing e-cigarettes in the U.S. without FDA authorization for lawful new product sales, thereby violating the FD&C Act. 

 

In addition to the violations outlined in the warning letters, retailers and manufacturers have been advised to address any similar or related violations promptly and to take all necessary actions to comply with the law. Failure to rectify these violations in a timely manner could result in further FDA actions, including injunctions, seizures, and/or civil penalties.

 

"FDA remains unwavering in enforcing the law," said John Verbeten, Director of the CTP's Office of Compliance and Enforcement. "We will continue to take appropriate steps and work alongside our federal enforcement partners to address unauthorized tobacco products, especially those most appealing to youth".

 

This latest round of warning letters represents another step in the FDA's ongoing effort to remove unauthorized e-cigarette products from the market, particularly those that attract younger audiences. 

 

To date, FDA has issued more than 700 warning letters to companies involved in manufacturing, selling, and/or distributing unauthorized new tobacco products, along with over 690 warning letters to retailers selling unauthorized tobacco products. 

 

Additionally, FDA has filed civil penalty complaints against more than 75 manufacturers and 150 retailers for distributing and/or selling unauthorized tobacco products.

 

As of October 30, 2024, FDA has approved 34 e-cigarette products and devices. The agency has provided a printable flyer listing all authorized e-cigarette products, which retailers can refer to in order to verify which products can be legally marketed and sold in the U.S. 

 

Entities that manufacture, import, sell, or distribute e-cigarettes without the required premarket authorization risk enforcement actions.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania's Act 57 vape directory regime will reach the end of its 120-day inventory transition period on Oct. 19. Nicotine-containing e-cigarettes intended for retail sale in the state that are not listed on the Attorney General's ENDS directory will then be barred from retail sale and treated as contraband subject to seizure, forfeiture and destruction. Manufacturers face annual product certification, brand- and style-based fees and a minimum $50,000 surety bond, while retailers and wholesalers must source through licensed channels and monitor the directory.
Regulations
Oct.08
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
At the 2026 NACS Show, Altria displayed Ploom devices alongside imagery of Marlboro-branded heated tobacco sticks, while also featuring RIOT Energy and Proper Wild non-nicotine products. The booth showcased on! PLUS nicotine pouches, including 12 mg variants not listed among FDA-authorized products as of October 9, and NJOY e-cigarettes. Altria also presented convenience-store traffic figures highlighting its retail presence. 2Firsts examines the company's expanded product portfolio, non-nicotine business activities and the regulatory status of products displayed at the show.
EXPO
Oct.10
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10